**Travel Burden and Clinical Presentation of Retinoblastoma: Analysis of 1,024 patients from 43 African Countries and 518 Patients from 40 European Countries**

Ido Didi Fabian, MD1,2, Andrew W Stacey, MD3, Allen Foster, FRCOphth1, Tero T Kivelä, MD4, Francis L. Munier, MD5, Naama Keren-Froim, B.Med.Sc.6, Nir Gomel, MD7, Nathalie Cassoux, MD, PhD8, Mandeep S. Sagoo, FRCS (Ed)9, M Ashwin Reddy, FRCOphth10, Lamis Al Harby, MD10, Marcia Zondervan, MBA1, Covadonga Bascaran, MD MSc1, Elhassan Abdallah, MD11, Shehu U Abdullahi, MD12, Sahadatou Adamou Boubacar, MD13, Dupe S Ademola-Popoola, FMCOph, FWACS14, Adedayo Adio, FWACS15, Ada E Aghaji, FMCOph MSc16, Silvia Alarcón Portabella, MD17, Amadou I Alfa Bio, MD18, Amany M Ali, MD19, Donjeta B Alia, MD20, Charlotta All-Eriksson, MD, PhD21, Argentino A Almeida, MD22, Khalifa M Alsawidi, MD23, Romanzo Antonino, MD24, Nicholas J Astbury, FRCS, FRCOphth1, Rose Atsiaya, OCO25, Julia Balaguer, MD, PhD26, Walentyna Balwierz, MD27, Honorio Barranco, MD, PhD26, Maja Beck Popovic, MD28, Sarra Benmiloud, MD29, Nissrine Bennani Guebessi, MD, PhD30, Rokia C Berete, MD, PhD31, Shelley J Biddulph, FC Ophthal32, Eva M Biewald, MD33, Sharon Blum, MD2, Nadia Bobrova, MD34, Marianna Boehme33, Norbert Bornfeld, MD33, Gabrielle C Bouda, MD35, Hédi Bouguila, MD, PhD36, Amaria Boumedane, MD37, Bénédicte G Brichard, MD, PhD38, Michael Capra, FRCPI39, Guilherme Castela, MD40, Jaume Català-Mora, MD, PhD41, Guillermo L Chantada, MD, PhD41, Violeta S Chernodrinska, MD, PhD42, Faraja S Chiwanga, MSc43, Krzysztof Cieslik, MD44, Codruta Comsa, MD45, Maria G Correa Llano, MD41, Monika Csóka, MD, PhD46, Isac V Da Gama, MD47, Alan Davidson, MBChB, MPhil48, Patrick De Potter, MD, PhD38, Laurence Desjardins, MD,49, Monica D Dragomir, MD, PhD45, Magritha Du Bruyn, MD50, Asmaa El Kettani, MD30, Amal M Elbahi, MD23, Dina Elgalaly, BPh51, Alaa M Elhaddad, MD, PhD51, Moawia M Ali Elhassan, MD52, Mahmoud M Elzembely, MD19, Vera A Essuman, FWACS53, Ted Grimbert A Evina, MD54, Oluyemi Fasina, FWACS55, Ana Fernández-Teijeiro, MD, PhD56, Moira Gandiwa, MD57, David García Aldana, MD58, Jennifer A Geel, MBChB, MMed32,59, Zelalem Gizachew, MD60, Pernille A Gregersen, MD61, Koffi M Guedenon, MD62, Theodora Hadjistilianou, MD63, Sadiq Hassan, MD, FWACS12, Stanislava Hederova, MD64, Laila Hessissen, MD65, Diriba F Hordofa, MD66, Marlies Hummlen, MD67, Kristina Husakova, MD64, Russo Ida, MD24, Vesna R Ilic, MD68, Helen Jenkinson, MD, PhD69, Theophile B Amani Kabesha, MD, PhD70, Rolande L Kabore, MD35, Abubakar Kalinaki, MD71, Noa Kapelushnik, MD2, Tamar Kardava, PhD72, Pavlin Kroumov Kemilev, MD42, Tomas Kepak, MD73, Zaza Khotenashvili, MD72, Artur Klett, MD, PhD74, Jess Elio Kosh Komba Palet, MD75, Dalia Krivaitiene, MD, PhD76, Mariana Kruger, MMed Paed, PhD77, Alice Kyara, BA43, Eva S Lachmann, MD78, Slobodanka Latinović, MD, PhD79, Karin Lecuona, MD80, Robert M Lukamba, MD81, Livia Lumbroso, MD49, Lesia Lysytsia, MD82, Erika Maka, MD46, Mayuri Makan, MD83, Chatonda Manda, MMed Ophth57, Nieves Martín Begue, MD, PhD17, Ibrahim O Matende, MD, MMed Ophth25, Marchelo Matua, BAPH84, Ismail Mayet, MD32, Freddy B Mbumba, MD, MMed Paed85, Aemero A Mengesha, MD86, Edoardo Midena, MD, PhD87, Furahini G Mndeme, MD88, Ahmed A Mohamedani, FRCPath89, Annette C Moll, MD, PhD90, Claude Moreira, MD, PhD91, Mchikirwa S Msina, MMed Ophth88, Gerald Msukwa, MMed Ophth57, Kangwa I Muma, MMed Ophth, FCOphth92, Gabriela Murgoi, MD45, Kareem O Musa, FWACS, FMCOphth, FICO93, Hamzah Mustak, MD80, Okwen M Muyen, MD94, Gita Naidu, MMed Paed, PhD32, Larisa Naumenko, MD, PhD95, Paule Aïda Ndoye Roth, MD, PhD96, Vladimir Neroev, MD, PhD97, Marina Nikitovic, MD, PhD68, Elizabeth D Nkanga, FMCOph98, Henry E Nkumbe, MD54, Mutale Nyaywa, MD, MMed Ophth, FCOphth99, Ghislaine Obono-Obiang, MD100, Ngozi C Oguego, MB, BS, FWASC, FAEH16, Andrzej Olechowski, MD44, Alexander Hugo Oscar, MD, PhD42, Peter Osei-Bonsu, MD, FWACS101, Sally L Painter, FRCOphth69, Vivian Paintsil, FWACP101, Luisa Paiva, MD102, Ruzanna Papyan, MD103, Raffaele Parrozzani, MD, PhD87, Manoj Parulekar, MS, FRCOphth69, Katarzyna Pawinska-Wasikowska, MD, PhD27, Sanja Perić, MD, PhD104, Remezo Philbert, MD105, Pavel Pochop, MD, PhD106, Vladimir G Polyakov, MD107, 108 , Manca T Pompe, MD, PhD109, Jonathan J Pons, MD110, Léa Raobela, MD111, Lorna A Renner, FRCPCH (UK)112, David Reynders, MD113, Dahiru Ribadu, FMCOph114, Mussagy M Riheia, MD115, Petra Ritter-Sovinz, MD116, Svetlana Saakyan, MD, PhD97, Azza MA Said, MD117, Sonsoles San Román Pacheco, MD118, Trish A Scanlan, MRCPI MSc43, Judy Schoeman, MSc113, Stefan Seregard, MD, PhD21, Sadik T Sherief, MD60, Sidi Sidi cheikh, MD, PhD119, Sónia Silva, MD40, Tetyana Sorochynska, MD, PhD34, Grace Ssali, MD120, Christina Stathopoulos, MD5, Branka Stirn Kranjc, MD, PhD109, David K Stones, MBChB, FCPaed121, Karel Svojgr, MD, PhD122, Fatoumata Sylla, MD123, Gevorg Tamamyan, MD, PhD103, Alketa Tandili, MD, PhD20, Bekim Tateshi, MD, PhD124, Tuyisabe Theophile, MSc125, Fousseyni Traoré, MD126, Harba Tyau-Tyau, MD127, Ali B Umar, MD, FMCPath12, Steen F Urbak, MD, PhD128, Tatiana L Ushakova, MD107, 108, Sandra Valeina, MD129, Milo van Hoefen Wijsard, MD90, Nevyana V Veleva-Krasteva, MD, PhD42, Maris Viksnins, MD129, Werner Wackernagel, MD130, Keith Waddell, DM, FRCP, FRCS, FRCOphth84, Patricia D Wade, MBBS131, Amina H Wali, MD, FMCOph Nigeria132, Amelia DC Wime, MD102, Charlotte Wolley Dod, MD17, Jenny M Yanga, MD133, Vera A Yarovaya, MD134, Andrey A Yarovoy, MD, PhD134, Ekhtelbenina Zein, MD135, Shirley Sharabi, PhD136, Katsiaryna Zhilyaeva, MD95, Othman AO Ziko, MD, PhD117, Richard Bowman, FRCOphth1,137

**Affiliations**

1International Centre for Eye Helath, London School of Hygiene & Tropical Medicine,

London, UK; 2The Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer,

Tel-Aviv University, Tel-Aviv, Israel; 3Department of Ophthalmology, University of

Washington, Seattle, WA, US; 4Ocular Oncology Service, Department of

Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki,

Finland; 5Jules-Gonin Eye Hospital, Fondation Asile de Aveugles, University of Lausanne, Lausanne, Switzerland; 6Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; 7Division of Ophthalmology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; 8Institut curie, université de Paris medicine Paris V Descartes, Paris, France; 9NIHR Biomedical Research Center for Ophthalmology at Moorfields Eye Hospital and UCL Institute of Ophthalmology and London Retinoblastoma Service, Royal London Hospital, London, UK; 10The Royal London Hospital, Barts Health NHS Trust, and Moorfields Eye Hospital NHS Foundation Trust, London, UK; 11Ophthalmology Department of Rabat, Mohammed V university, Rabat, Morocco; 12Bayero University, Aminu Kano Teaching Hospital, Kano, Nigeria; 13National Hospital of Niamey, Niamey, Niger; 14University of Ilorin & University of IlorinTeaching Hospital, Ilorin, Kwara State, Nigeria; 15Department of Ophthalmology, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria; 16Department of Ophthalmology, College of Medicine, University of Nigeria, Enugu, Nigeria; 17Department of Pediatric Ophthalmology, Hospital Vall d’Hebron, Barcelona, Spain; 18University of Parakou, Parakou, Benin; 19Pediatric Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt; 20University Hospital Center ‘Mother Theresa’, Tirana, Albania; 21St Erik Eye Hospital, Stockholn, Sweden; 22Beira Central Hospital, Beira, Mozambique; 23Tripoli Eye Hospital, Tripoli University, Tripoli, Libya; 24Bambino Gesù IRCCS Children’s Hospital, Rome, Italy; 25Light House For Christ Eye Center, Mombasa, Kenya; 26Pediatric Oncology Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain; 27Institute of Pediatrics, Jagiellonian University Medical College, Childrens University Hospital of Krakow, Krakow, Poland; 28Unit of Pediatric Hematology-Oncology, University Hospital CHUV, Lausanne, Switzerland; 29Department of Pediatric Oncology, University Hassan II Fès, Fez, Morocco; 30Center Hospitalier et Universitaire Ibn Rochd, Casablanca, Morocco; 31Ophthalmologic Department of the Teaching Hospital of Treichville, Abidjan, Côte d’ivoire; 32University of the Witwatersrand, Johannesburg, South Africa; 33University Hospital Essen, Department of Ophthalmology, University Duisburg-Essen, Essen, Germany; 34The Filatov Institute of Eye diseases and Tissue Therapy, Odessa, Ukraine; 35Center Hospitalier Universitaire Yalgado Ouédraogo de Ouagadougou, Ouagadougou, Burkina Faso; 36Institut Hédi-Raïs d’Ophtalmologie de Tunis, Faculté de Médecine de Tunis, Université Tunis El Manar, Tunis, Tunisia; 37Etablissement Hospitalière Spécialise Emir Abdelkader CEA Service d’Oncologie Pédiatrique, Oran, Algeria; 38Cliniques Universitaires Saint-Luc, Brussel, Belgium; 39Our Lady’s Children’s Hospital, Dublin, Ireland; 40Centro Hospital Universitário de Coimbra, University of Coimbra, Coimbra, Portugal; 41Hospital Sant Joan de Déu, Barcelona, Spain; 42Eye Clinic, University Hospital ‘Alexandrovska’, Department of Ophthalmology, Medical University, Sofia, Bulgaria; 43Muhimbili National Hospital, Dar es Salaam, Tanzania; 44Department of Ophthalmology, The Children’s Memorial Health Institute, Warsaw, Poland; 45Oncology Institute ‘Prof. Dr. Al. Trestioreanu’ Bucharest, Romania; 46Semmelweis University Budapest, Budapest, Hungary; 47Quelimane central Hospital, Quelimane, Mozambique; 48Red Cross Children’s War Memorial Hospital and the University of Cape Town, Cape Town, South Africa; 49Institut curie, Paris, France; 50University of KwaZulu-Natal, Durban, South Africa; 51Children’s Cancer Hospital Egypt 57357, Cairo, Egypt; 52Oncology Department, National Cancer Institute, University of Gezira, Wadi Madani, Sudan; 53Ophthalmology Unit, Department of Surgery, School of Medicine and Dentistry, University of Ghana, Accra, Ghana; 54Magrabi ICO Cameroon Eye Institute, Yaounde, Cameroon; 55Department of Ophthalmology, University College Hospital/University of Ibadan, Ibadan, Oyo State, Nigeria; 56Hospital Universitario Virgen Macarena, Sevilla, Spain; 57Lions Sight First Eye Hospital, Queen Elizabeth Central Hospital, Blantyre, Malawi; 58Servicio Andaluz de Salud (SAS), Sevilla, Spain; 59Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa; 60Addis Ababa University, School of Medicine, Department of Ophthalmology, Addis Ababa, Ethiopia; 61Department of Clinical Genetics, and Center for Rare Disorders, Aarhus University Hopspital, Aarhus, Denmark; 62Département de Pédiatrie, CHU Sylvanus Olympio, Université de Lomé, Lomé, Togo; 63Retinoblastoma referral center, University of Siena, Siena, Italy; 64University Childrens’ Hospital, Bratislava, Slovakia; 65Pediatric Hematology and Oncology Department of Rabat – Mohammed V University, Rabat, Morocco; 66Department of Pediatrics and Child Health, Jimma University Medical Center, Jimma, Ethiopia; 67Department of Ophthalmology, Oslo University Hospital, Oslo, Norway; 68Institute for Oncology and Radiology, Belgrade, Serbia; 69Birmingham Children’s Hospital Eye Department, Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, UK; 70Bukavu Eye Clinic – Bukavu Official University, Bukavu, DRC; 71Makerere University College of Health Sciences, Department of Ophthalmology, Kamplala, Uganda; 72Ophthalmology Department, Central Children’s Hospital of Georgia, Tbilisi, Georgia; 73University Hospital Brno, Masaryk University and ICRC/St. Anna University Hospital, Brno, Czech Republic; 74East Tallinn Central Hospital, Tallinn, Estonia; 75Oncologue Pédiatre Responsable d’Unité de Bangui, Bangui, Central African Republic; 76Chidren’s Ophthalmology Department, Chidren’s Hospital of Vilnius, University Hospital Santaros Clinic, Vilnius, Lithuania; 77Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa; 78University Hospital Hamburg-Eppendorf, Hamburg, Germany; 79Clinical Center Of Vojvodina – University Eye Clinic, Eye Research Foundation Vidar – Latinović, Novi Sad, Serbia; 80Division of Ophthalmology, University of Cape Town, Cape Town, South Africa; 81University Clinics of Lubumbashi ,University of Lubumbashi, Lubumbashi, DRC; 82The Okhmatdyt National Children’s Hospital, Kiev, Ukraine; 83Sekuru Kaguvi Eye Unit, Parirenyatwa Group of Hospitals, Harare, Zimbabwe; 84Ruharo Eye Hospital, Mbarara, Uganda; 85Botswana Government – Scottish Livingstone Hospital, Molepolole, Botswana; 86Department of Ophthalmology, Jimma University, Jimma, Ethiopia; 87Department of Ophthalmology, University of Padova, Padova, Italy; 88Kilimanjaro Christian Medical Center, Moshi, Tanzania; 89Pathology Department, Faculty of Medicine, University of Gezira, Wadi Madani, Sudan; 90Department of Ophthalmology, Amsterdam UMC, Amsterdam, Netherlands; 91Service d’oncologie pédiatrique de l’hôpital Aristide le Dantec, Dakar, Senegal; 92Ministry of Health, Lusaka, Zambia; 93Department of Ophthalmology, Lagos University Teaching Hospital/College of Medicine of the University of Lagos, Lagos, Nigeria; 94Abii Specialists Hospital, Bamenda, Cameroon; 95N.N. Alexandrov National Cancer Center of Belarus, Minsk, Belarus; 96Cheikh Anta DIOP University of Dakar, Le Dantec Hospital, Dakar, Senegal; 97Moscow Helmholtz Research Institute of Eye Diseases, Moscow, Russia; 98Calabar Children’s Eye Center, Department of Ophthalmology University of Calabar Teaching Hospital Calabar Cross River State, Nigeria; 99Arthur Davison Children’s Hospital, Ndola, Zambia; 100Chu Angondje Cancerologie, Libreville, Gabon; 101Komfo Anokye Teaching Hospital, Kumasi, Ghana; 102National Ophthalmological Institute of Angola, Luanda, Angola; 103Yerevan State Medical University, Department of Oncology and Pediatric Cancer and Blood Disorders Center of Armenia, Hematology Center after R.H. Yeolyan, Yerevan, Armenia; 104University Hospital Center Zagreb, Zagreb, Croatia; 105Center Hospitaliere Universitaire de Kamenge, Bujumbura, Burundi; 106Department of Ophthalmology for Children and Adults, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic; 107Head and Neck Tumors Department, SRI of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Center of Oncology of Russian Federation, Moscow, Russian Federation; 108Medical Academy of Postgraduate Education, Moscow, Russia; 109Univ. Medical Center Ljubljana, Univ.Eye Hospital Ljubljana, Ljubljana, Slovenia; 110Good Shepherd Hospital, Siteki, Swaziland; 111Center Hospitalier Universitaire Joseph Ravoahangy Andrianavalona, Antananarivo, Madagascar; 112University of Ghana School of Medicine and Dentistry, Korle Bu Teaching Hospital, Accra, Ghana; 113University of Pretoria, Pretoria, South Africa; 114Federal Medical Center, Yola, Nigeria; 115Nampula central hospital, Nampula, Mozambique; 116Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology/Oncology, Medical University of Graz, Graz, Austria; 117Ophthalmology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; 118Pediatric Hemato-Oncology, Hospital Universitario Infantil La Paz, Madrid, Spain; 119Ophthalmology department, Nouakchott Medical University, Nouakchott, Mauritania; 120Mulago National Referral and Teaching Hospital, Kamplala, Uganda; 121Department of Paediatrics and Child Health, University of the Free Sate, Bloemfontein, South Africa; 122Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic; 123Africa Institute of Tropical Ophtalmology, Bamako, Mali; 124University Eye Clinic, Skopje, Macedonia; 125Kabgayi Eye Unit, Gitarama, Rwanda; 126Pediatric Oncology Service, Gabriel Toure Hospital, Bamako, Mali; 127Université Adam Barka, Adam Barka, Chad; 128Department of ophthalmology, Aarhus University Hospital, Aarhus, Denmark; 129Children’s Clinical University Hospital, Riga, Latvia; 130Department of Ophthalmology, Medical University Graz, Graz, Austria; 131Jos University Teaching Hospital, Jos, Nigeria; 132National Eye Center Kaduna, Kaduna, Nigeria; 133Service d’Ophtalmologie, Cliniques Universitaires de Kinshasa, Université de Kinshasa, Kinshasa, DRC; 134S.Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russia; 135Assistante Hospitalo – Universitaire, Faculte de Medecine de Nouakchott Medecin Oncopediatre, Center National d’Oncologie, Nouakchott, Mauritania; 136Radiology Department, Sheba Medical Center, Ramat-Gan, Israel, 137Ophthalmology Department, Great Ormond Street Children’s Hospital, London, UK.

**Correspondence to**:

Ido Didi Fabian, MD

London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK

didi@didifabian.com

Tel: +44(0) 20 7958 8346

**Synopsis**

In Europe, travel distance to retinoblastoma center is not a barrier to early diagnosis. In Africa, most cases that present live close to treatment centers, yet present late, and those living far do not present for treatment.

**Abstract**

**Background**

The travel distance from home to a treatment center, which may impact the stage at diagnosis, has not been investigated for retinoblastoma, the most common childhood eye cancer. We aimed to investigate the travel burden and its impact on clinical presentation in a large sample of retinoblastoma patients from Africa and Europe.

**Methods**

A cross-sectional analysis including 518 treatment-naïve retinoblastoma patients residing in 40 European countries and 1,024 treatment-naïve retinoblastoma patients residing in 43 African countries.

**Results**

Capture rate was 42.2% of expected patients from Africa and 108.8% from Europe. African patients were older (95% CI (-12.4)-(-5.4), p<0.001), had fewer cases of familial retinoblastoma (95% CI 2.0-5.3, p<0.001), and presented with more advanced disease (95% CI 6.0-9.8, p<0.001); 43.4% and 15.4% of Africans had extraocular retinoblastoma and distant metastasis at time of diagnosis, respectively, compared to 2.9% and 1.0% of the Europeans. To reach a retinoblastoma center, European patients travelled 421.8 km compared to Africans who travelled 185.7 km (p<0.001). On regression analysis, lower-national income level, African residence and older age (p<0.001), but not travel distance (p=0.19), were risk factors for advanced disease.

**Conclusions**

Fewer than half the expected number of retinoblastoma patients presented to African referral centers in 2017, suggesting poor awareness or other barriers to access. Despite the relatively shorter distance travelled by African patients, they presented with later stage disease. Health education about retinoblastoma is needed for carers and health workers in Africa in order to increase capture rate and promote early referral

**Introduction**

Rare cancers, defined as having an incidence of less than six cases per 100,000 population per year,[1] pose a particular burden on patients and professionals alike because of the need for specialist care, frequent lack of standardized treatments, and lack of funding for research.[2,3] It is not uncommon to have only 1 or 2 specialized referral centers in a country for a given type of rare cancer, to which most cases are referred. Such a policy of centralized tertiary centers may result in reduced access and a high travel burden on patients, which can lead to poorer quality of life, advanced disease at diagnosis, late treatment, and worse prognosis.[4,5]

Retinoblastoma is a rare, potentially deadly, childhood cancer. Its incidence is believed to be constant across populations, ranging from 1:16,000-18,000 live births.[6] In most countries only few specialized retinoblastoma centers exist. In Europe, for example, there is a single center in France, two in the UK and three in Russia, all in Moscow. Travel burden associated with retinoblastoma, to the best of our knowledge, has not been explored. This information, which also reflects on the accessibility to tertiary centers and their catchment area, is important for healthcare planning.

Prognosis of patients with retinoblastoma has improved significantly over the past 50 years to reach over 90% 5-year survival in Europe.[7–9] These improvements are attributed to several factors, including the implementation of national strategies associated with retinoblastoma referral pathways, and the introduction of novel and improved treatment modalities, several of which were developed in European specialized referral centers.[10–13] Indeed, in the field of retinoblastoma, Europe serves as a potential model for under-resourced regions of the world. In Africa, where birth rate is higher, resulting in higher retinoblastoma prevalence, these improvements in survival have not been observed. Reports on retinoblastoma from Africa are scarce and anecdotal evidence suggests that survival rates are as low as 50%,[14,15] and in some regions of Sub-Saharan Africa are even less than 30%.[16]

We have recently reported the stage at presentation of more than 4,000 newly diagnosed retinoblastoma patients from over 150 countries analysed by national-income level.[17] The aim of the present study is to use the data from all countries in Africa and Europe to: (1) investigate and compare the travel burden experienced by patients, (2) compare the stage at time of diagnosis and (3) investigate risk factors for advanced disease at time of diagnosis. Such information is important to better understand the current gaps in retinoblastoma service provision and to inform policy makers at national and international levels.

**Methods**

The study methodology, data collection and quality assurance process have been described in detail previously.[17] Briefly, the data were collected through a 1-year cross-sectional analysis of treatment-naïve retinoblastoma patients who presented to retinoblastoma referral centers across the world from January 1, 2017, to December 31, 2017. Data on country of residence, sex and laterality of retinoblastoma were considered essential minimum criteria for inclusion. In the present analysis, patients that resided in African and European countries were included. The study was approved by the London School of Hygiene & Tropical Medicine institutional review board (reference no. 14574) in accordance with the tenets of the Declaration of Helsinki. Participating centers, according to local institutional and national guidelines, applied to and received ethics clearance in their countries.

Data collected from medical charts included patient country of residence, initial clinical sign leading to referral, distance travelled from home to retinoblastoma center, sex, family history of retinoblastoma, age at time of diagnosis at retinoblastoma center, tumor laterality, and stage according to the 8th edition of the American Joint Committee on Cancer (AJCC) clinical Tumor, Node, Metastasis, Hereditary (cTNMH) scheme,[18] and the International Retinoblastoma Staging System.[19] For travel distance calculation, a Google-based map was used and the orthodromic distance (i.e. “as the crow flies”) between home and the retinoblastoma center was measured. In case both were in the same city or site, the distance was considered to be zero, unless mentioned otherwise by the retinoblastoma center that submitted the data. Data on national-income level, crude birth rate, country surface area and population size were retrieved from the United Nations World Population Prospects.[20]

Statistical analysis

Analyses were performed using R software[21] and IBM SPSS statistics v25.0 (IBM corp, Chicago, IL). The predicted number of new retinoblastoma patients per country was calculated as follows: country population\*crude birth rate/1,000/17,000.[22] The predicted number does not take into account deviations from the average percentage with familial retinoblastoma, in which the risk of the offspring is ~1/2 rather than 1/17,000. The predicted number per continent was the sum for all countries in that continent. Fisher’s exact test and Student’s *t*-test was used to compare categorical and continuous variables between groups. A one-way ANOVA was used to test differences in the age at the time of diagnosis between the continents and the Kruskal-Wallis test to test for differences in travel distance between the continents. Binomial logistic regression was used to model the effect of income level, continent, travel distance from home to retinoblastoma center, age at diagnosis, family history of retinoblastoma, and tumor laterality on the likelihood of children having advanced disease at presentation (cT4). A value of p<0.05 was considered significant and data throughout the manuscript are presented as mean (standard deviation (SD) with 95% confidence interval (CI)).

**Results**

The analytic sample included 1,542 newly diagnosed retinoblastoma patients. Of these, 518 (33.6%) resided in 40 European countries and 1,024 (66.4%) in 43 African countries. Using an average incidence figure of 1/17,000 live births,[6] the observed capture rates were 42.2% and 108.8% of expected patients from Africa and Europe, respectively.

Clinical data were available for both the African and European sub-cohorts for over 90% of patients, with the exception of travel distance, which was available for 81.5% and 84.6% of the patients, respectively. **Table 1** shows the clinical data of the study patients by continent.

|  |
| --- |
| **Table 1. Clinical data of 518 European and 1,024 African retinoblastoma patients.**  |
| **Parameter** | **European sample, n (%)** | **African sample, n (%)** | **Significance** |
| **Travel distance from home to retinoblastoma center**1 | p<0.001 |
| Mean distance in km (Std., 95% CI) | 421.8 (814.6; 328.6-537.5) | 185.7 (201.0; 168.0-205.2) |  |
| Reported cases | 396/468 (84.6) | 736/903 (81.5) |
| **Age at diagnosis**  | p<0.001 |
| Mean age in months (Std., 95% CI) | 22.0 (27.6; 19.7-24.4) | 30.9 (21.0; 28.7-32.8) |  |
| Reported cases | 514/518 (99.2) | 1,015 (99.1) |
| **Sex** | p=0.75 |
| Male | 280 (54.0) | 544 (53.1) |  |
| Female | 238 (46.0) | 480 (46.9) |
| Reported cases | 518/518 (100) | 1,024/1,024 (100) |
| **Laterality**  | p=0.07 |
| Unilateral | 357 (68.9) | 751 (73.3) |  |
| Bilateral | 161 (31.1) | 273 (26.7) |
| Reported cases | 518/518 (100) | 1,024/1,024 (100) |
| **Familial retinoblastoma**  | p<0.001 |
| No | 468 (91.6) | 910 (97.2) |  |
| Yes | 43 (8.4) | 26 (2.8) |
| Reported cases | 511/518 (98.6) | 936/1,024 (91.4) |
| **Primary tumor (T)** | p<0.001 |
| cT1 | 76 (14.9) | 32 (3.3) | ≤cT2 vs >cT2 |
| cT2 | 237 (46.6) | 134 (13.9) |
| cT3 | 192 (37.7) | 465 (48.3) |
| cT4 | 4 (0.8) | 331 (34.4) |
| Reported cases | 509/518 (98.3) | 962/1,024 (93.9) |
| **Regional lymph node (N)** | p<0.001 |
| NX | 34 (6.6) | 265 (26.8) | N0 vs N1 |
| N0 | 482 (93.2) | 636 (64.4) |
| N1 | 1 (0.2) | 86 (8.7) |
| Reported cases | 517/518 (99.8) | 987/1,024 (96.4) |
| **Distant metastasis (M)** | p<0.001 |
| M0 | 513 (99.0) | 830 (84.6) | M0 vs M12 |
| cM1 | 1 (0.2) | 110 (11.2) |
| pM1 | 4 (0.8) | 41 (4.2) |
| Reported cases | 518/518 (100) | 981/1,024 (95.8) |
| **Extraocular retinoblastoma** | p<0.001 |
| No | 503 (97.1) | 561 (56.6) |  |
| Yes3 | 15 (2.9) | 430 (43.4) |
| Reported cases | 518/518 (100) | 991/1,024 (96.8) |
| 150/518 (9.7%) European and 121/1,024 (11.8%) African retinoblastomapatients travelled across borders for diagnosis and primary treatment (not included in the analysis). 2M1 = cM1+pM1. 3 based on the International Retinoblastoma Staging System.[19]NA – not applicable.  |

Travel burden and retinoblastoma center catchment area

Overall, the mean travel distance from home to a retinoblastoma center was 233.3 km (468.78; 207.0-259.0). To reach an retinoblastoma center within the country of residence, patients from European countries travelled on average more than twice the distance compared to patients from African countries: 421.8km (814.6; 328.6-537.5) and 185.7km (201.0; 168.0-205.2), respectively (p<0.001, **eTable 1** in the appendix). **Figure 1** shows the number of retinoblastoma centers by country and continent (see **eFigure 1** in the appendix for geographical location of the centers). No significant differences were found in the mean number of retinoblastoma centers per country in Africa and Europe: 1.8 (1.8; 1.2-2.4) and 1.4 (0.9; 1.1-1.7), respectively (p=0.22). Similarly, on analysis of the mean country population size and country surface area, differences between African and European countries were non-significant (p=0.32 and p=0.89, respectively). The catchment area of each retinoblastoma center in Africa and Europe is represented in **Figure 2** by the mean travel distance ± Std. While the distribution of retinoblastoma centers in Europe covers the entire continent, in many African countries, large parts remain underserviced.

Presentation to retinoblastoma center

*Age at time of diagnosis*

For the entire sample, the mean age at time of diagnosis at a retinoblastoma center was 27.9 months (95% CI 26.7-29.0): 22.0 months (27.6; 19.7-24.4) for European patients compared to 30.9 months (21.0; 28.7-32.8) for those from Africa (diff = (-8.9), 95% CI (-12.4)-(-5.4), p<0.001).

*Bilateral and familial retinoblastoma*

Overall, 28.1% of the patients presented with bilateral disease, and 4.5% had a family history of retinoblastoma. Of the African patients, 26.7% had bilateral disease at the time of diagnosis compared to 31.1% of the European patients (OR 0.8, 95% CI 0.6-1.0, p=0.07). A positive family history was reported for 2.8% vs 8.4% of the African and European patients, respectively (OR 3.2, 95% CI 2.0-5.3, p<0.001).

Referral to an retinoblastoma center for screening in case of positive family history of retinoblastoma was uncommon in Africa as compared to Europe: 3/26 (11.5%) of the familial cases in Africa vs 31/42 (73.8%) in Europe (OR 20, 95% CI 5.3-100.0, p<0.001). All three screened African patients were staged cT1 at time of diagnosis. Of the African familial cases, 57.7% had advanced intraocular (cT3) or extraocular retinoblastoma (cT4) at time of diagnosis. In comparison, of the European familial cases, 64.3%, 31.0%, and 4.8% were staged cT1, cT2 and cT3, respectively.

*Tumor staging*

Overall, the most common cTNM stages were cT3 (44.7%), N0 (74.3%), and M0 (89.6%). Significantly more patients from African countries as compared to European countries had at time of diagnosis advanced retinoblastoma (i.e. >cT2; OR 7.7, 95% CI 6.0-9.8, p<0.001), extraocular retinoblastoma (OR 25.7, 95% CI 15.1-43.6, p<0.001), lymph node involvement (OR 65.2, 95% CI 9.0-469.7, p<0.001), and metastasis (OR 18.7, 95% CI 7.6-45.8, p<0.001). Overall, 43.4% and 15.4% of the African patients had at time of diagnosis extraocular retinoblastoma and distant metastasis, respectively, compared to 2.9% and 1.0% of the European patients, respectively.

Risk factors for advanced disease at time of diagnosis

Lower-national-income level, African continent, older age at presentation, familial retinoblastoma, and bilateral retinoblastoma (p≤0.010), but not distance from home to retinoblastoma center (p=0.19), were found to be significant factors for the prediction of cT4 category (i.e. extraocular disease). On logistic regression, national-income level, continent, and age at presentation were found to be independent, significant predictors for cT4 category (**Table 2**). On further analysis by continent, no predictors were found for the European subgroup, whereas for the African, older age and lower-income level (p<0.001) were found to be significant predictors of cT4 category (**eTable 2** in the appendix).

|  |
| --- |
| **Table 2. Predictors of advanced retinoblastoma disease at presentation (cT4): univariate and multivariate analysis.**  |
| **Variable** | **Category** | **B** | **S.E.** | **Corrected p-value** | **OR** | **95% CI for OR** |
|  |  |  |  |  |  | **Lower** | **Upper** |
| **Univariate analysis** |
| **Income level** | Low vs lower-middle | 1.04 | 0.14 | <0.001 | 2.82 | 2.13 | 3.74 |
| Low vs upper-middle | 1.25 | 0.15 | <0.001 | 3.50 | 2.60 | 4.70 |
| Low vs high | 1.89 | 0.34 | <0.001 | 6.64 | 3.44 | 12.82 |
| Lower-middle vs upper-middle | 1.47 | 0.31 | <0.001 | 4.33 | 2.38 | 7.90 |
| Lower-middle vs high | 2.32 | 0.50 | <0.001 | 10.19 | 3.80 | 27.35 |
| Upper-middle vs high | 3.18 | 1.04 | <0.001 | 23.96 | 3.11 | 184.62 |
| **Continent** | Africa vs Europe  | 0.84 | 0.10 | <0.001 | 2.32 | 1.90 | 2.82 |
| **Familial retinoblastoma** | Yes vs no | 1.51 | 0.52 | 0.001 | 4.54 | 1.64 | 12.57 |
| **Bilaterality** | Yes vs no | 0.38 | 0.15 | 0.010 | 1.46 | 1.10 | 1.94 |
| **Distance from home to Rb center1** |  |  |  | 0.19 |  |  |  |
| **Age at diagnosis1** |  |  |  | <0.001 |  |  |  |
| **Multivariate analysis (binomial logistic regression)** |
| **Income level** | Lower-middle  | 0.90 | 0.15 | <0.001 | 2.45 | 1.83 | 3.30 |
| Upper-middle  | 1.48 | 0.34 | <0.001 | 4.38 | 2.26 | 8.47 |
| High  | 3.08 | 1.18 | 0.001 | 21.74 | 2.14 | 220.82 |
| **Continent** | Europe | 2.34 | 0.62 | <0.001 | 10.37 | 3.07 | 35.01 |
| **Age at diagnosis2** | ≥24 months | -1.33 | 0.16 | <0.001 | 0.27 | 0.19 | 0.37 |
| **Constant** |  | 1.07 | 0.16 | <0.001 | 0.34 |  |  |
| 1t-test for numerical variables. 2median age = 24.2 months (categorical variable). OR – odds ratio, CI – confidence interval.  |

**Discussion**

Our findings confirm a large disparity in the presentation patterns of retinoblastoma between patients from African and European countries. Patients from Africa were significantly older, nearly half of them had extraocular spread at time of diagnosis, and nearly one fifth had distant metastasis. Of the European patients, less than 3% had extraocular tumor spread and only 1% had metastatic spread at time of diagnosis. Patients from lower-income level countries, those from the African continent, and older patients at time of diagnosis were at increased risk to have advanced retinoblastoma. Interestingly, distance patients travelled in order to reach a retinoblastoma referral center did not play a role in this risk. These results are in contrast to previous analyses of other forms of cancer, including breast, colon, lung, and skin melanoma,[23–26] as well as rare cancers such as Merkel cell carcinoma,[27] in which high travel burden correlated with advanced-disease stage. Noteworthy, all of the above referenced studies were single-center rather than multicenter multinational studies, as the present one.

Analysis of the travel burden, however, in conjunction with data on the number of retinoblastoma centers in African and European countries, and demographic data, including country population and surface area, suggest a more complex picture. Patients from African countries travelled less than half the distance compared to European patients in order to reach a specialized retinoblastoma treatment center. Assuming that nearly all retinoblastoma centers in the participating African countries were contacted and recruited, our findings suggest that these centers serve mainly patients that reside in close vicinity.

Taking into account the low capture rate in Africa, underlying causes for the findings of this study are multifactorial; they include poor awareness by carers and health workers, lack of knowledge about clinical presentation by health workers, travel distance and cost to reach a specialized retinoblastoma treatment center, and probably the absence of specialized retinoblastoma treatment centers in some parts of Africa.

It is well-documented that poor awareness of retinoblastoma both by the public and health workers can lead to delays in diagnosis.[28–31] Delayed retinoblastoma diagnosis, in turn, leads to poor outcome.[32–34] Poor awareness and health education is likely to be the main factor for those cases that reside in proximity to a treatment center; yet, presented late. Initiatives are addressing this need by creating twinning programs that link centers from higher- and lower-resource countries, as well as interventions such as public awareness campaigns, and health worker education.[29,31,35–39] There is a pressing need, to promote this action at national and global level. In a rare curable cancer such as Rb, with a finite number of patients worldwide, such action is feasible.

Barriers to health care in Africa have been reported in relation to several medical fields, including oncology,[40,41] ophthalmology,[42–46] and pediatrics.[42,44,47] Most barriers, whether financial, structural (i.e. accessibility), lack of transport, poor roads, were also found relevant in the context of retinoblastoma in Africa.[48–50] Possible solutions should be inclusive and account for all factors; most are not in the scope of the present study. Number and distribution, however, of retinoblastoma centers in a country is a matter that warrants further discussion. The need for and number of retinoblastoma centers derive first and foremost from the number of new retinoblastoma cases in a country. There should be enough centers with an appropriate distribution to serve all patients within a country. On the other hand, there should not be too many, as expert centers need to remain “vivid”, an ability that relates directly to the number of cases managed, as was shown in other rare malignancies.[51] In this sense, European and African countries face different challenges. In Europe, with a low birth rate and therefore low prevalence of retinoblastoma, the need for a treatment center in countries with 1-2 new cases per year is questionable. In Africa, with a high birth rate and increasing population, the situation is more complex. New retinoblastoma centers will be needed where there is a large population (10 million population and 20-30 new retinoblastoma cases/year) with no available center. The number and distribution of retinoblastoma treatment centers need to be tailored to the country’s requirements.

Familial retinoblastoma was significantly more common in European than in African countries. A possible explanation is the high survival rate of hereditary cases in Europe due to early diagnosis and efficient treatments. This possibly could explain the high capture rate of retinoblastoma in Europe too, higher than the predicted annual number. Further studies are warranted to better understand the trends in retinoblastoma incidence in Europe. Three quarters of the European familial cases were screened for retinoblastoma (i.e. examined before clinical signs were evident) and most were diagnosed with early disease stage. In Africa, screening rate was as low as 11.5% of the familial cases, lower than previously reported in “developing countries” outside Africa.[52] Screening may result in less invasive treatments being needed, resulting in higher chances for eye salvage and better vision.[53,54] Retinoblastoma patients from both continents should receive future counselling regarding the need for screening of their offspring, especially the ~30% that presented with bilateral disease whose children have a nearly 50% chance of developing retinoblastoma. Interestingly, rates of bilateral cases were similar between Africa and Europe. Most of them are known to result from sporadic germline mutations. The proportion of cases with familial retinoblastoma who presented with bilateral disease was also similar. Given the risk factor analysis, which showed that lower-income level and African continent were independently associated with advanced disease, it is possible that other, unrecorded variables are responsible for disease progression before diagnosis is made in Africa, as well as for tendency to present with bilateral retinoblastoma. Further studies should explore these possibilities.

Our study has limitations. First, the orthodromic distance was used as a surrogate for the travel burden, whereas other related factors that may play a role were not taken into account, especially travel costs, time costs, loss of parental income, availability and mode of transportation, road conditions, availability of transport, and the actual distance travelled from home to a specialized referral retinoblastoma center. Second, our study was cross-sectional by design and some of the data were collected in a retrospective manner (centers that were recruited after January, 2017), with the inherent limitations of such a design. Nevertheless, we were able to collect data from an unprecedented number of retinoblastoma centers and countries and to perform a quality and assurance process to make sure that the data are accurate. Third, our sample was a convenience sample, and although repeated attempts were made to reach every retinoblastoma treatment center in Africa and Europe, it is possible that some were missed. Notably, centers in Namibia (n=1), Sierra Leone (n=1) and Somalia (n=1) that were contacted did not join in the study, hence no information on these centers was available. In addition, only 1 out of 2 centers in Kenya, and 1 out of 2 in Algeria, joined in the study, and similarly, no information was available on those centers that did not join in.

In summary, our findings show that in European countries, travel distance from home to retinoblastoma center is not a barrier to early disease diagnosis. European patients travel on average more than 400 km and >60% present at stage cT2 or earlier. In Africa, the picture is more complex – patients travel on average less than 200 km, yet >80% present at stage cT3 or worse, suggesting that factors other than geographic distance to retinoblastoma center play a role in late disease diagnosis. Poor awareness and education by both care givers and health workers, other barriers to access, and possibly, number and distribution of specialist retinoblastoma treatment centers in those African countries in which the population is underserved, are key factors that warrant intervention on national and international levels. . Familial retinoblastoma is more common in Europe than in Africa, most probably due to death related to late disease presentation, and screening of patients at risk of developing retinoblastoma is more common in Europe. Comprehensive counselling of families and patients with germline disease (i.e. bilateral retinoblastoma and/or positive family history) may be found useful in order to detect the disease at early stage to increase survival rates in this highly curable malignancy.

**Acknowledgment**

Competing interests: None declared.

Ethics approval: Institutional Review Board of the London School of Hygiene & Tropical Medicine institutional review board (number 14574).

**Author Contributions**

**Conception and design**: Ido Didi Fabian, Allen Foster, Richard Bowman

**Financial support**: NA

**Administrative support**: Covadonga Bascaran, Marcia Zondervan

**Collection and assembly of data**: All authors

**Data analysis and interpretation**: Ido Didi Fabian, Nathalie Cassoux, Allen Foster, Tero T Kivelä, Francis Munier, M Ashwin Reddy, Mandeep S Sagoo, Andrew S Stacey

**Statistical analysis**: Andrew S Stacey

**Manuscript drafting**: Ido Didi Fabian, Allen Foster, Andrew S Stacey, Richard Bowman

**Critical revision of the manuscript for important intellectual content**: All authors

**Final approval of manuscript**: All authors

**Accountable for all aspects of the work**: All authors

**References**

1 Gatta G, Capocaccia R, Trama A, *et al.* The burden of rare cancers in europe. *Adv Exp Med Biol* 2010;**686**:285–303. doi:10.1007/978-90-481-9485-8\_17

2 Komatsubara KM, Carvajal RD. The promise and challenges of rare cancer research. *Lancet Oncol* 2016;**17**:136–8. doi:10.1016/s1470-2045(15)00485-4

3 Graf von der Schulenburg J‐M PF. Rare cancers—Rarity as a cost and value argument. *J Cancer Policy* 2017;**11**:54–9.

4 Ambroggi M, Biasini C, Del Giovane C, *et al.* Distance as a Barrier to Cancer Diagnosis and Treatment: Review of the Literature. *Oncologist* 2015;**20**:1378–85. doi:10.1634/theoncologist.2015-0110

5 Gatta G, Van Der Zwan JM, Casali PG, *et al.* Rare cancers are not so rare: The rare cancer burden in Europe. *Eur J Cancer* 2011;**47**:2493–511. doi:10.1016/j.ejca.2011.08.008

6 Kivelä T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. *Br J Ophthalmol* 2009;**93**:1129–31. doi:10.1136/bjo.2008.150292

7 MacCarthy A, Birch JM, Draper GJ, *et al.* Retinoblastoma: Treatment and survival in Great Britain 1963 to 2002. *Br J Ophthalmol* 2009;**93**:38–9. doi:10.1136/bjo.2008.139626

8 MacCarthy A, Draper GJ, Steliarova-Foucher E, *et al.* Retinoblastoma incidence and survival in European children (1978-1997). Report from the Automated Childhood Cancer Information System project. *Eur J Cancer* 2006;**42**:2092–102. doi:10.1016/j.ejca.2006.06.003

9 Sant M, Capocaccia R, Badioni V, *et al.* Survival for retinoblastoma in Europe. *Eur J Cancer* 2001;**37**:730–5. doi:10.1016/s0959-8049(01)00011-9

10 Munier FL, Gaillard M-C, Balmer a., *et al.* Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. *Br J Ophthalmol* 2012;**96**:1078–83. doi:10.1136/bjophthalmol-2011-301450

11 STALLARD HB. Irradiation of retinoblastoma (glioma retinae). *Lancet (London, England)* 1952;**1**:1046–9.http://www.ncbi.nlm.nih.gov/pubmed/14928558 (accessed 15 Oct 2015).

12 Kingston JE, Hungerford JL, Madreperla SA, *et al.* Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. *Arch Ophthalmol (Chicago, Ill 1960)* 1996;**114**:1339–43.http://www.ncbi.nlm.nih.gov/pubmed/8906024 (accessed 20 Oct 2015).

13 Lagendijk JJ. A microwave heating technique for the hyperthermic treatment of tumours in the eye, especially retinoblastoma. *Phys Med Biol* 1982;**27**:1313–24. doi:10.1088/0031-9155/27/11/002

14 Waddell KM, Kagame K, Ndamira A, *et al.* Clinical features and survival among children with retinoblastoma in Uganda. *Br J Ophthalmol* 2015;**99**:387–90. doi:10.1136/bjophthalmol-2014-305564

15 Canturk S, Qaddoumi I, Khetan V, *et al.* Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators. *Br J Ophthalmol* 2010;**94**:1432–6. doi:10.1136/bjo.2009.168062

16 Gichigo EN, Kariuki-Wanyoike MM, Kimani K, *et al.* [Retinoblastoma in Kenya: survival and prognostic factors]. *Ophthalmologe* 2015;**112**:255–60. doi:10.1007/s00347-014-3123-z

17 Global Retinoblastoma Study Group. Global Retinoblastoma Presentation and Analysis by National Income Level. *JAMA Oncol* 2020;**6**:1–12. doi:10.1001/jamaoncol.2019.6716

18 Mallipatna AC, Gallie BL, Chévez-Barrios P et al. *Retinoblastoma. In: Amin MB, Edge SB, Greene FL, et al., eds. AJCC Cancer Staging Manual. 8th ed.* New York: : Springer 2017.

19 Chantada G, Doz F, Antoneli CBG, *et al.* A proposal for an international retinoblastoma staging system. *Pediatr Blood Cancer* 2006;**47**:801–5. doi:10.1002/pbc.20606

20 United Nations, Department of Economic and Social Affairs PD (2017). World Population Prospects: The 2017 Revision, Volume I: Comprehensive Tables (ST/ESA/SER.A/399).

21 R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.r-project.org/

22 Seregard S, Lundell G, Svedberg H, *et al.* Incidence of retinoblastoma from 1958 to 1998 in Northern Europe: Advantages of birth cohort analysis. *Ophthalmology* 2004;**111**:1228–32. doi:10.1016/j.ophtha.2003.10.023

23 Massarweh NN, Chiang YJ, Xing Y, *et al.* Association between travel distance and metastatic disease at diagnosis among patients with colon cancer. *J Clin Oncol* 2014;**32**:942–8. doi:10.1200/JCO.2013.52.3845

24 Campbell NC, Elliott AM, Sharp L, *et al.* Rural and urban differences in stage at diagnosis of colorectal and lung cancers. *Br J Cancer* 2001;**84**:910–4. doi:10.1054/bjoc.2000.1708

25 Stitzenberg KB, Thomas NE, Dalton K, *et al.* Distance to diagnosing provider as a measure of access for patients with melanoma. *Arch Dermatol* 2007;**143**:991–8. doi:10.1001/archderm.143.8.991

26 Scoggins JF, Fedorenko CR, Donahue SMA, *et al.* Is Distance to provider a barrier to care for medicaid patients with breast, colorectal, or lung cancer? *J Rural Heal* 2012;**28**:54–62. doi:10.1111/j.1748-0361.2011.00371.x

27 Jain R, Menzin J, Lachance K, *et al.* Travel burden associated with rare cancers: The example of Merkel cell carcinoma. *Cancer Med* 2019;**8**:2580–6. doi:10.1002/cam4.2085

28 Dimaras H, Dimba EAO, Gallie BL. Challenging the global retinoblastoma survival disparity through a collaborative research effort. Br. J. Ophthalmol. 2010. doi:10.1136/bjo.2009.174136

29 Rodriguez-Galindo C, Wilson MW, Chantada G, *et al.* Retinoblastoma: One world, one vision. In: *Pediatrics*. 2008. doi:10.1542/peds.2008-0518

30 Owoeye JFA, Afolayan EAO, Ademola-Popoola DS. Retinoblastoma--a clinico-pathological study in Ilorin, Nigeria. *Afr J Health Sci* Published Online First: 2006. doi:10.4314/ajhs.v13i1.30825

31 Leander C, Fu LC, Peña A, *et al.* Impact of an education program on late diagnosis of retinoblastoma in Honduras. *Pediatr Blood Cancer* Published Online First: 2007. doi:10.1002/pbc.21052

32 Chawla B, Hasan F, Azad R, *et al.* Clinical presentation and survival of retinoblastoma in Indian children. Br. J. Ophthalmol. 2016;**100**:172–8. doi:10.1136/bjophthalmol-2015-306672

33 Nyamori JM, Kimani K, Njuguna MW, *et al.* Retinoblastoma referral pattern in Kenya. *Middle East Afr J Ophthalmol* 2014;**21**:321–7. doi:10.4103/0974-9233.142270

34 Chantada G, Fandiño A, Manzitti J, *et al.* Late diagnosis of retinoblastoma in a developing country. *Arch Dis Child* 1999;**80**:171–4.http://www.ncbi.nlm.nih.gov/pubmed/10325735 (accessed 23 Jan 2019).

35 Bowman R. Retinoblastoma: A curable, rare and deadly blinding disease. *Community Eye Heal J* 2018;**31**:1–4.http://www.ncbi.nlm.nih.gov/pubmed/29915456 (accessed 20 Jan 2019).

36 Traoré F, Sylla F, Togo B, *et al.* Treatment of retinoblastoma in Sub-Saharan Africa: Experience of the paediatric oncology unit at Gabriel Toure Teaching Hospital and the Institute of African Tropical Ophthalmology, Bamako, Mali. *Pediatr Blood Cancer* 2018;**65**:e27101. doi:10.1002/pbc.27101

37 Hill JA, Kimani K, White A, *et al.* Achieving optimal cancer outcomes in East Africa through multidisciplinary partnership: a case study of the Kenyan National Retinoblastoma Strategy group. *Global Health* 2016;**12**:23. doi:10.1186/s12992-016-0160-1

38 Wilimas JA, Wilson MW, Haik BG, *et al.* Development of retinoblastoma programs in Central America. *Pediatr Blood Cancer* 2009;**53**:42–6. doi:10.1002/pbc.21984

39 Qaddoumi I, Nawaiseh I, Mehyar M, *et al.* Team management, twinning, and telemedicine in retinoblastoma: a 3-tier approach implemented in the first eye salvage program in Jordan. *Pediatr Blood Cancer* 2008;**51**:241–4. doi:10.1002/pbc.21489

40 Akuoko CP, Armah E, Sarpong T, *et al.* Barriers to early presentation and diagnosis of breast cancer among African women living in sub-Saharan Africa. *PLoS One* 2017;**12**. doi:10.1371/journal.pone.0171024

41 Rosser JI, Hamisi S, Njoroge B, *et al.* Barriers to cervical cancer screening in rural Kenya: Perspectives from a provider survey. *J Community Health* 2015;**40**:756–61. doi:10.1007/s10900-015-9996-1

42 Mwende J, Bronsard A, Mosha M, *et al.* Delay in presentation to hospital for surgery for congenital and developmental cataract in Tanzania. *Br J Ophthalmol* 2005;**89**:1478–82. doi:10.1136/bjo.2005.074146

43 Kessy JP, Lewallen S. Poverty as a barrier to accessing cataract surgery: a study from Tanzania. *Br J Ophthalmol* 2007;**91**:1114–6. doi:10.1136/bjo.2006.112474

44 Bronsard A, Geneau R, Shirima S, *et al.* Why are children brought late for cataract surgery? Qualitative findings from Tanzania. *Ophthalmic Epidemiol*;**15**:383–8. doi:10.1080/09286580802488624

45 Gyasi M., Amoaku WM., Asamany D. Barriers to cataract surgical uptake in the upper east region of Ghana. *Ghana Med J* 2010;**41**. doi:10.4314/gmj.v41i4.55285

46 Bowman RJC, Faal H, Jatta B, *et al.* Longitudinal study of trachomatous trichiasis in The Gambia: Barriers to acceptance of surgery. *Investig Ophthalmol Vis Sci* 2002;**43**:936–40. doi:10.1097/00132578-200210000-00012

47 Rutherford ME, Mulholland K, Hill PC. How access to health care relates to under-five mortality in sub-Saharan Africa: Systematic review. Trop. Med. Int. Heal. 2010;**15**:508–19. doi:10.1111/j.1365-3156.2010.02497.x

48 Lukamba RM, Yao J-JA, Kabesha TA, *et al.* Retinoblastoma in Sub-Saharan Africa: Case Studies of the Republic of Côte d’Ivoire and the Democratic Republic of the Congo. *J Glob Oncol* 2018;:1–8. doi:10.1200/jgo.17.00056

49 James BO, Ajayi SO, Ogun OA, *et al.* Factors influencing time to diagnosis of childhood cancer in Ibadan, Nigeria. *Afr Health Sci* 2009;**9**:247–53.

50 Nyamori JM, Kimani K, Njuguna MW, *et al.* Retinoblastoma referral pattern in kenya. *Middle East Afr J Ophthalmol* 2014;**21**:321–7. doi:10.4103/0974-9233.142270

51 Blay JY, Honoré C, Stoeckle E, *et al.* Surgery in reference centers improves survival of sarcoma patients: a nationwide study. *Ann Oncol* 2019;**30**:1143–53. doi:10.1093/annonc/mdz124

52 Chantada GL, Dunkel IJ, Qaddoumi I, *et al.* Familial retinoblastoma in developing countries. *Pediatr Blood Cancer* 2009;**53**:338–42. doi:10.1002/pbc.21970

53 Imhof SM, Moll AC, Schouten-van Meeteren AYN. Stage of presentation and visual outcome of patients screened for familial retinoblastoma: nationwide registration in the Netherlands. *Br J Ophthalmol* 2006;**90**:875–8. doi:10.1136/bjo.2005.089375

54 Soliman SE, Dimaras H, Khetan V, *et al.* Prenatal versus Postnatal Screening for Familial Retinoblastoma. *Ophthalmology* 2016;**123**:2610–7. doi:10.1016/j.ophtha.2016.08.027

**Figure Legends**

**Figure 1.** Number of retinoblastoma centers in (A) Africa and (B) Europe. \*Centers in Namibia (n=1), Sierra Leone (n=1) and Somalia (n=1) that were contacted did not join the study, hence no information was available from these centers. Of the two known Kenyan centers and two known Algerian centers that were contacted, only one from each country has joined in the study.

**Figure 2.** Retinoblastoma center catchment area in Africa and Europe. The red circles represent the mean patient travel distance and green circles, the travel distance Std. Patients in European countries travelled in average significantly longer distances (421.8 km±814.6) compared to patients from African countries (185.7 km±201.0) in order to reach an Retinoblastoma center (p<0.001). Superimposing the red and green circles on the map, Retinoblastoma centers in European countries cover the whole continent, whereas in Africa, large parts in many African countries remain uncovered.